194 related articles for article (PubMed ID: 12546685)
1. Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes.
Ruderman NB; Cacicedo JM; Itani S; Yagihashi N; Saha AK; Ye JM; Chen K; Zou M; Carling D; Boden G; Cohen RA; Keaney J; Kraegen EW; Ido Y
Biochem Soc Trans; 2003 Feb; 31(Pt 1):202-6. PubMed ID: 12546685
[TBL] [Abstract][Full Text] [Related]
2. AMP-activated protein kinase regulation of fatty acid oxidation in the ischaemic heart.
Hopkins TA; Dyck JR; Lopaschuk GD
Biochem Soc Trans; 2003 Feb; 31(Pt 1):207-12. PubMed ID: 12546686
[TBL] [Abstract][Full Text] [Related]
3. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation.
Tomas E; Tsao TS; Saha AK; Murrey HE; Zhang Cc Cc; Itani SI; Lodish HF; Ruderman NB
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16309-13. PubMed ID: 12456889
[TBL] [Abstract][Full Text] [Related]
4. LKB1 and the regulation of malonyl-CoA and fatty acid oxidation in muscle.
Thomson DM; Brown JD; Fillmore N; Condon BM; Kim HJ; Barrow JR; Winder WW
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1572-9. PubMed ID: 17925454
[TBL] [Abstract][Full Text] [Related]
5. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects.
Luna V; Casauban L; Sajan MP; Gomez-Daspet J; Powe JL; Miura A; Rivas J; Standaert ML; Farese RV
Diabetologia; 2006 Feb; 49(2):375-82. PubMed ID: 16395615
[TBL] [Abstract][Full Text] [Related]
6. Acute regulation of fatty acid oxidation and amp-activated protein kinase in human umbilical vein endothelial cells.
Dagher Z; Ruderman N; Tornheim K; Ido Y
Circ Res; 2001 Jun; 88(12):1276-82. PubMed ID: 11420304
[TBL] [Abstract][Full Text] [Related]
7. Role of AMP-activated protein kinase in mechanism of metformin action.
Zhou G; Myers R; Li Y; Chen Y; Shen X; Fenyk-Melody J; Wu M; Ventre J; Doebber T; Fujii N; Musi N; Hirshman MF; Goodyear LJ; Moller DE
J Clin Invest; 2001 Oct; 108(8):1167-74. PubMed ID: 11602624
[TBL] [Abstract][Full Text] [Related]
8. Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats.
Kraegen EW; Saha AK; Preston E; Wilks D; Hoy AJ; Cooney GJ; Ruderman NB
Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E471-9. PubMed ID: 16234268
[TBL] [Abstract][Full Text] [Related]
9. AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome.
McCarty MF
Med Hypotheses; 2005; 64(6):1211-5. PubMed ID: 15823720
[TBL] [Abstract][Full Text] [Related]
10. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects.
Bandyopadhyay GK; Yu JG; Ofrecio J; Olefsky JM
Diabetes; 2006 Aug; 55(8):2277-85. PubMed ID: 16873691
[TBL] [Abstract][Full Text] [Related]
11. Insulin stimulation of glucose uptake fails to decrease palmitate oxidation in muscle if AMPK is activated.
Winder WW; Holmes BF
J Appl Physiol (1985); 2000 Dec; 89(6):2430-7. PubMed ID: 11090599
[TBL] [Abstract][Full Text] [Related]
12. AMP-activated protein kinase regulation and action in skeletal muscle during exercise.
Musi N; Yu H; Goodyear LJ
Biochem Soc Trans; 2003 Feb; 31(Pt 1):191-5. PubMed ID: 12546683
[TBL] [Abstract][Full Text] [Related]
13. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle.
Collier CA; Bruce CR; Smith AC; Lopaschuk G; Dyck DJ
Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E182-9. PubMed ID: 16478780
[TBL] [Abstract][Full Text] [Related]
14. AMPK activation is not critical in the regulation of muscle FA uptake and oxidation during low-intensity muscle contraction.
Raney MA; Yee AJ; Todd MK; Turcotte LP
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E592-8. PubMed ID: 15547141
[TBL] [Abstract][Full Text] [Related]
15. Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity.
Ruderman NB; Saha AK; Kraegen EW
Endocrinology; 2003 Dec; 144(12):5166-71. PubMed ID: 14500570
[TBL] [Abstract][Full Text] [Related]
16. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase.
Davis BJ; Xie Z; Viollet B; Zou MH
Diabetes; 2006 Feb; 55(2):496-505. PubMed ID: 16443786
[TBL] [Abstract][Full Text] [Related]
17. Role of AMP--activated protein kinase in the control of glucose homeostasis.
Barnes BR; Zierath JR
Curr Mol Med; 2005 May; 5(3):341-8. PubMed ID: 15892653
[TBL] [Abstract][Full Text] [Related]
18. Insulin signalling downstream of protein kinase B is potentiated by 5'AMP-activated protein kinase in rat hearts in vivo.
Longnus SL; Ségalen C; Giudicelli J; Sajan MP; Farese RV; Van Obberghen E
Diabetologia; 2005 Dec; 48(12):2591-601. PubMed ID: 16283248
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome: adenosine monophosphate-activated protein kinase and malonyl coenzyme A.
Ruderman NB; Saha AK
Obesity (Silver Spring); 2006 Feb; 14 Suppl 1():25S-33S. PubMed ID: 16642960
[TBL] [Abstract][Full Text] [Related]
20. Influence of malonyl-CoA and palmitate concentration on rate of palmitate oxidation in rat muscle.
Merrill GF; Kurth EJ; Rasmussen BB; Winder WW
J Appl Physiol (1985); 1998 Nov; 85(5):1909-14. PubMed ID: 9804598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
